Published 1 year ago • loading... • Updated 1 year ago
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
On May 28, 2025, Servier announced in Boston that it ranked among the top pharmaceutical companies in PatientView's 2024 Corporate Reputation survey in the U.S. and globally.
This ranking follows a global survey conducted from December 2024 to March 2025, based on responses from 372 U.S. patient groups representing over 13 million patients.
Servier, headquartered in France, operates in 140 countries with over 22,000 employees and invests heavily in oncology, allocating nearly 70% of its R&D budget to this area.
Patient organizations placed Servier at the top in categories such as Data Transparency, Integrity, Beyond the Pill initiatives, and Engagement in Research and Development. Nicolas Garnier highlighted that this honor signifies their sustained dedication to prioritizing patients in every aspect of their work.
The recognition reinforces Servier's commitment to patient engagement, access to medicines, and delivering solutions beyond medication, as emphasized by Vice President Wendy Poage.